RECURRENT MANTLE CELL LYMPHOMA

This early-phase trial tests whether combining two targeted drugs (pacritinib and a BTK inhibitor) is safe and can shrink tumors in people with mantle cell lymphoma that came back or didn't respond to prior therapy. About 10 adults will receive the drug combo. The goal is to find…

This study tests a combination of two treatments for mantle cell lymphoma that has returned or stopped responding to standard therapy. Patients receive their own immune cells that have been modified to recognize and attack the cancer, along with a drug that blocks cancer growth. …

This early-stage study tests whether giving two targeted drugs together is feasible for people with certain B-cell lymphomas that have returned or stopped responding to prior therapy. The drugs, zanubrutinib and sonrotoclax, work by blocking proteins that help cancer cells surviv…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…

This phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…

This study tests whether a faster dose increase of the drug sonrotoclax, given with other medicines, is safe for people with certain blood cancers (CLL, SLL, or mantle cell lymphoma). The cancers may be new, returned, or not responding to treatment. The goal is to see if this qui…

This study tests whether ultra low dose radiation, given before or after targeted therapy, can help control mantle cell lymphoma that has returned or stopped responding to treatment. About 80 adults with this type of cancer will receive radiation to shrink tumors, aiming to impro…

This study tests two drugs, glofitamab and obinutuzumab, in 20 people with mantle cell lymphoma that returned or didn't respond after CAR T-cell therapy. Glofitamab helps the immune system attack cancer cells, while obinutuzumab blocks cancer growth. The goal is to see if this co…

This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…